Drugs / CY-219
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07539688 | May 2026 → Mar 2029 expected | diffuse large B-cell lymphoma, large B-cell lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CY-219 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07539688 ↗ |